The global Cellular and Gene Therapy Product market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Cellular and Gene Therapy Product, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cellular and Gene Therapy Product.
Report Scope
The Cellular and Gene Therapy Product market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cellular and Gene Therapy Product market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cellular and Gene Therapy Product manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol-Myers Squibb
New York Blood Center
Johnson & Johnson
Cleveland Cord Blood Center
Organogenesis
Duke University School of Medicine
Colorado Cord Blood Banking
MD Anderson Cancer Center
LifeSouth Community Blood Centers
Bloodworks Northwest
Amgen
Novartis Pharmaceuticals
Castle Creek Biosciences
Spark Therapeutics
Vericel
Dendreon Pharmaceuticals
Enzyvant Therapeutics GmbH
Mallinckrodt
Gilead Sciences
bluebird bio
Segment by Type
Cellular Immunotherapies
Cancer Vaccines
Autologous and Allogeneic Cells
Segment by Application
Blood Cancer
Prostate Cancer
Skin Cancer
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cellular and Gene Therapy Product manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cellular and Gene Therapy Product in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Cellular and Gene Therapy Product Market Overview
1.1 Product Overview and Scope of Cellular and Gene Therapy Product
1.2 Cellular and Gene Therapy Product Segment by Type
1.2.1 Global Cellular and Gene Therapy Product Market Value Comparison by Type (2024-2030)
1.2.2 Cellular Immunotherapies
1.2.3 Cancer Vaccines
1.2.4 Autologous and Allogeneic Cells
1.3 Cellular and Gene Therapy Product Segment by Application
1.3.1 Global Cellular and Gene Therapy Product Market Value by Application: (2024-2030)
1.3.2 Blood Cancer
1.3.3 Prostate Cancer
1.3.4 Skin Cancer
1.3.5 Other
1.4 Global Cellular and Gene Therapy Product Market Size Estimates and Forecasts
1.4.1 Global Cellular and Gene Therapy Product Revenue 2019-2030
1.4.2 Global Cellular and Gene Therapy Product Sales 2019-2030
1.4.3 Global Cellular and Gene Therapy Product Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Cellular and Gene Therapy Product Market Competition by Manufacturers
2.1 Global Cellular and Gene Therapy Product Sales Market Share by Manufacturers (2019-2024)
2.2 Global Cellular and Gene Therapy Product Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Cellular and Gene Therapy Product Average Price by Manufacturers (2019-2024)
2.4 Global Cellular and Gene Therapy Product Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Cellular and Gene Therapy Product, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cellular and Gene Therapy Product, Product Type & Application
2.7 Cellular and Gene Therapy Product Market Competitive Situation and Trends
2.7.1 Cellular and Gene Therapy Product Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cellular and Gene Therapy Product Players Market Share by Revenue
2.7.3 Global Cellular and Gene Therapy Product Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cellular and Gene Therapy Product Retrospective Market Scenario by Region
3.1 Global Cellular and Gene Therapy Product Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Cellular and Gene Therapy Product Global Cellular and Gene Therapy Product Sales by Region: 2019-2030
3.2.1 Global Cellular and Gene Therapy Product Sales by Region: 2019-2024
3.2.2 Global Cellular and Gene Therapy Product Sales by Region: 2025-2030
3.3 Global Cellular and Gene Therapy Product Global Cellular and Gene Therapy Product Revenue by Region: 2019-2030
3.3.1 Global Cellular and Gene Therapy Product Revenue by Region: 2019-2024
3.3.2 Global Cellular and Gene Therapy Product Revenue by Region: 2025-2030
3.4 North America Cellular and Gene Therapy Product Market Facts & Figures by Country
3.4.1 North America Cellular and Gene Therapy Product Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Cellular and Gene Therapy Product Sales by Country (2019-2030)
3.4.3 North America Cellular and Gene Therapy Product Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Cellular and Gene Therapy Product Market Facts & Figures by Country
3.5.1 Europe Cellular and Gene Therapy Product Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Cellular and Gene Therapy Product Sales by Country (2019-2030)
3.5.3 Europe Cellular and Gene Therapy Product Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cellular and Gene Therapy Product Market Facts & Figures by Country
3.6.1 Asia Pacific Cellular and Gene Therapy Product Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Cellular and Gene Therapy Product Sales by Country (2019-2030)
3.6.3 Asia Pacific Cellular and Gene Therapy Product Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Cellular and Gene Therapy Product Market Facts & Figures by Country
3.7.1 Latin America Cellular and Gene Therapy Product Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Cellular and Gene Therapy Product Sales by Country (2019-2030)
3.7.3 Latin America Cellular and Gene Therapy Product Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cellular and Gene Therapy Product Market Facts & Figures by Country
3.8.1 Middle East and Africa Cellular and Gene Therapy Product Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Cellular and Gene Therapy Product Sales by Country (2019-2030)
3.8.3 Middle East and Africa Cellular and Gene Therapy Product Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Cellular and Gene Therapy Product Sales by Type (2019-2030)
4.1.1 Global Cellular and Gene Therapy Product Sales by Type (2019-2024)
4.1.2 Global Cellular and Gene Therapy Product Sales by Type (2025-2030)
4.1.3 Global Cellular and Gene Therapy Product Sales Market Share by Type (2019-2030)
4.2 Global Cellular and Gene Therapy Product Revenue by Type (2019-2030)
4.2.1 Global Cellular and Gene Therapy Product Revenue by Type (2019-2024)
4.2.2 Global Cellular and Gene Therapy Product Revenue by Type (2025-2030)
4.2.3 Global Cellular and Gene Therapy Product Revenue Market Share by Type (2019-2030)
4.3 Global Cellular and Gene Therapy Product Price by Type (2019-2030)
5 Segment by Application
5.1 Global Cellular and Gene Therapy Product Sales by Application (2019-2030)
5.1.1 Global Cellular and Gene Therapy Product Sales by Application (2019-2024)
5.1.2 Global Cellular and Gene Therapy Product Sales by Application (2025-2030)
5.1.3 Global Cellular and Gene Therapy Product Sales Market Share by Application (2019-2030)
5.2 Global Cellular and Gene Therapy Product Revenue by Application (2019-2030)
5.2.1 Global Cellular and Gene Therapy Product Revenue by Application (2019-2024)
5.2.2 Global Cellular and Gene Therapy Product Revenue by Application (2025-2030)
5.2.3 Global Cellular and Gene Therapy Product Revenue Market Share by Application (2019-2030)
5.3 Global Cellular and Gene Therapy Product Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bristol-Myers Squibb
6.1.1 Bristol-Myers Squibb Corporation Information
6.1.2 Bristol-Myers Squibb Description and Business Overview
6.1.3 Bristol-Myers Squibb Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bristol-Myers Squibb Cellular and Gene Therapy Product Product Portfolio
6.1.5 Bristol-Myers Squibb Recent Developments/Updates
6.2 New York Blood Center
6.2.1 New York Blood Center Corporation Information
6.2.2 New York Blood Center Description and Business Overview
6.2.3 New York Blood Center Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.2.4 New York Blood Center Cellular and Gene Therapy Product Product Portfolio
6.2.5 New York Blood Center Recent Developments/Updates
6.3 Johnson & Johnson
6.3.1 Johnson & Johnson Corporation Information
6.3.2 Johnson & Johnson Description and Business Overview
6.3.3 Johnson & Johnson Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Johnson & Johnson Cellular and Gene Therapy Product Product Portfolio
6.3.5 Johnson & Johnson Recent Developments/Updates
6.4 Cleveland Cord Blood Center
6.4.1 Cleveland Cord Blood Center Corporation Information
6.4.2 Cleveland Cord Blood Center Description and Business Overview
6.4.3 Cleveland Cord Blood Center Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Cleveland Cord Blood Center Cellular and Gene Therapy Product Product Portfolio
6.4.5 Cleveland Cord Blood Center Recent Developments/Updates
6.5 Organogenesis
6.5.1 Organogenesis Corporation Information
6.5.2 Organogenesis Description and Business Overview
6.5.3 Organogenesis Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Organogenesis Cellular and Gene Therapy Product Product Portfolio
6.5.5 Organogenesis Recent Developments/Updates
6.6 Duke University School of Medicine
6.6.1 Duke University School of Medicine Corporation Information
6.6.2 Duke University School of Medicine Description and Business Overview
6.6.3 Duke University School of Medicine Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Duke University School of Medicine Cellular and Gene Therapy Product Product Portfolio
6.6.5 Duke University School of Medicine Recent Developments/Updates
6.7 Colorado Cord Blood Banking
6.6.1 Colorado Cord Blood Banking Corporation Information
6.6.2 Colorado Cord Blood Banking Description and Business Overview
6.6.3 Colorado Cord Blood Banking Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Colorado Cord Blood Banking Cellular and Gene Therapy Product Product Portfolio
6.7.5 Colorado Cord Blood Banking Recent Developments/Updates
6.8 MD Anderson Cancer Center
6.8.1 MD Anderson Cancer Center Corporation Information
6.8.2 MD Anderson Cancer Center Description and Business Overview
6.8.3 MD Anderson Cancer Center Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.8.4 MD Anderson Cancer Center Cellular and Gene Therapy Product Product Portfolio
6.8.5 MD Anderson Cancer Center Recent Developments/Updates
6.9 LifeSouth Community Blood Centers
6.9.1 LifeSouth Community Blood Centers Corporation Information
6.9.2 LifeSouth Community Blood Centers Description and Business Overview
6.9.3 LifeSouth Community Blood Centers Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.9.4 LifeSouth Community Blood Centers Cellular and Gene Therapy Product Product Portfolio
6.9.5 LifeSouth Community Blood Centers Recent Developments/Updates
6.10 Bloodworks Northwest
6.10.1 Bloodworks Northwest Corporation Information
6.10.2 Bloodworks Northwest Description and Business Overview
6.10.3 Bloodworks Northwest Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Bloodworks Northwest Cellular and Gene Therapy Product Product Portfolio
6.10.5 Bloodworks Northwest Recent Developments/Updates
6.11 Amgen
6.11.1 Amgen Corporation Information
6.11.2 Amgen Cellular and Gene Therapy Product Description and Business Overview
6.11.3 Amgen Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Amgen Cellular and Gene Therapy Product Product Portfolio
6.11.5 Amgen Recent Developments/Updates
6.12 Novartis Pharmaceuticals
6.12.1 Novartis Pharmaceuticals Corporation Information
6.12.2 Novartis Pharmaceuticals Cellular and Gene Therapy Product Description and Business Overview
6.12.3 Novartis Pharmaceuticals Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Novartis Pharmaceuticals Cellular and Gene Therapy Product Product Portfolio
6.12.5 Novartis Pharmaceuticals Recent Developments/Updates
6.13 Castle Creek Biosciences
6.13.1 Castle Creek Biosciences Corporation Information
6.13.2 Castle Creek Biosciences Cellular and Gene Therapy Product Description and Business Overview
6.13.3 Castle Creek Biosciences Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Castle Creek Biosciences Cellular and Gene Therapy Product Product Portfolio
6.13.5 Castle Creek Biosciences Recent Developments/Updates
6.14 Spark Therapeutics
6.14.1 Spark Therapeutics Corporation Information
6.14.2 Spark Therapeutics Cellular and Gene Therapy Product Description and Business Overview
6.14.3 Spark Therapeutics Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Spark Therapeutics Cellular and Gene Therapy Product Product Portfolio
6.14.5 Spark Therapeutics Recent Developments/Updates
6.15 Vericel
6.15.1 Vericel Corporation Information
6.15.2 Vericel Cellular and Gene Therapy Product Description and Business Overview
6.15.3 Vericel Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Vericel Cellular and Gene Therapy Product Product Portfolio
6.15.5 Vericel Recent Developments/Updates
6.16 Dendreon Pharmaceuticals
6.16.1 Dendreon Pharmaceuticals Corporation Information
6.16.2 Dendreon Pharmaceuticals Cellular and Gene Therapy Product Description and Business Overview
6.16.3 Dendreon Pharmaceuticals Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Dendreon Pharmaceuticals Cellular and Gene Therapy Product Product Portfolio
6.16.5 Dendreon Pharmaceuticals Recent Developments/Updates
6.17 Enzyvant Therapeutics GmbH
6.17.1 Enzyvant Therapeutics GmbH Corporation Information
6.17.2 Enzyvant Therapeutics GmbH Cellular and Gene Therapy Product Description and Business Overview
6.17.3 Enzyvant Therapeutics GmbH Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Enzyvant Therapeutics GmbH Cellular and Gene Therapy Product Product Portfolio
6.17.5 Enzyvant Therapeutics GmbH Recent Developments/Updates
6.18 Mallinckrodt
6.18.1 Mallinckrodt Corporation Information
6.18.2 Mallinckrodt Cellular and Gene Therapy Product Description and Business Overview
6.18.3 Mallinckrodt Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Mallinckrodt Cellular and Gene Therapy Product Product Portfolio
6.18.5 Mallinckrodt Recent Developments/Updates
6.19 Gilead Sciences
6.19.1 Gilead Sciences Corporation Information
6.19.2 Gilead Sciences Cellular and Gene Therapy Product Description and Business Overview
6.19.3 Gilead Sciences Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Gilead Sciences Cellular and Gene Therapy Product Product Portfolio
6.19.5 Gilead Sciences Recent Developments/Updates
6.20 bluebird bio
6.20.1 bluebird bio Corporation Information
6.20.2 bluebird bio Cellular and Gene Therapy Product Description and Business Overview
6.20.3 bluebird bio Cellular and Gene Therapy Product Sales, Revenue and Gross Margin (2019-2024)
6.20.4 bluebird bio Cellular and Gene Therapy Product Product Portfolio
6.20.5 bluebird bio Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cellular and Gene Therapy Product Industry Chain Analysis
7.2 Cellular and Gene Therapy Product Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cellular and Gene Therapy Product Production Mode & Process
7.4 Cellular and Gene Therapy Product Sales and Marketing
7.4.1 Cellular and Gene Therapy Product Sales Channels
7.4.2 Cellular and Gene Therapy Product Distributors
7.5 Cellular and Gene Therapy Product Customers
8 Cellular and Gene Therapy Product Market Dynamics
8.1 Cellular and Gene Therapy Product Industry Trends
8.2 Cellular and Gene Therapy Product Market Drivers
8.3 Cellular and Gene Therapy Product Market Challenges
8.4 Cellular and Gene Therapy Product Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Bristol-Myers Squibb
New York Blood Center
Johnson & Johnson
Cleveland Cord Blood Center
Organogenesis
Duke University School of Medicine
Colorado Cord Blood Banking
MD Anderson Cancer Center
LifeSouth Community Blood Centers
Bloodworks Northwest
Amgen
Novartis Pharmaceuticals
Castle Creek Biosciences
Spark Therapeutics
Vericel
Dendreon Pharmaceuticals
Enzyvant Therapeutics GmbH
Mallinckrodt
Gilead Sciences
bluebird bio
听
听
*If Applicable.
